Articles tagged with: Sean R_ Hosein

Canadian study links food insecurity to detectable viral loads and decreased CD4+ cells

published: December, 12, 2017 Written by // CATIE - HIV and Hep C Info Resource Categories // Social Media, As Prevention , Hep B and C, Food, Nutrition and Recipes, Treatment Guidelines -including when to start, Research, CATIE - HIV and Hep C Info Resource, Health, Treatment, Living with HIV, Media

Researchers propose “broad multisector interventions that address income, housing affordability, substance use and mental health issues” to address the high degree of food insecurity in their study. From CATIE, Sean R. Hosein reports.

Canadian study links food insecurity to detectable viral loads and decreased CD4+ cells

- Canadian study of people with HIV and hepatitis C co-infection finds that limited access to food is associated with higher levels of HIV in the blood and 10% fewer CD4+ immune cells. - Ontario research reports 70% of HIV-positive participants had experienced food insecurity over the past year, six times greater than HIV-negative people. - Researchers say addressing underlying food insecurity could improve treatment adherence and health outcomes of people living with HIV. Researchers who e

What’s next for long-acting HIV drugs?

published: November, 22, 2017 Written by // CATIE - HIV and Hep C Info Resource Categories // CATIE, As Prevention , Current Affairs, Treatment Guidelines -including when to start, Research, CATIE - HIV and Hep C Info Resource, Health, Treatment

Two phase III trials are underway with long-acting (LA) formulations of HIV drugs. From CATIE, Sean R. Hosein reports.

What’s next for long-acting HIV drugs?

Two phase III trials are underway with long-acting (LA) formulations of HIV drugs. These trials will explore the safety and effectiveness of LA formulations in people new to HIV treatment (Flair) and in people who are treatment experienced (Atlas). The interim results from these two pivotal studies should be available in the latter half of 2018. If the results from Flair and Atlas are favourable, the manufacturer of the LA drugs, Viiv Healthcare, will submit a dossier of the data to regulator

Canadian researchers call for improved integration of family planning care for HIV-positive women

published: November, 15, 2017 Written by // CATIE - HIV and Hep C Info Resource Categories // CATIE - HIV and Hep C Info Resource

A team of Canadian researchers has analysed a comprehensive survey of HIV-positive women living in British Columbia, Ontario and Quebec. From CATIE, Sean R. Hosein reports.

Canadian researchers call for improved integration of family planning care for HIV-positive women

- Canadian study finds 60% of pregnancies among HIV-positive women were unintended. - Among HIV-positive women, unintentional pregnancies were more common if they were younger, single or born in Canada. - Researchers highlight the need to integrate family planning within comprehensive HIV care. A team of Canadian researchers has analysed a comprehensive survey of HIV-positive women living in British Columbia, Ontario and Quebec. The survey focused on pregnancy-related issues. The researcher

Investigating where patients go when they leave HIV care

published: November, 06, 2017 Written by // CATIE - HIV and Hep C Info Resource Categories // Social Media, As Prevention , CATIE, General Health, Treatment Guidelines -including when to start, Research, Sexual Health, International , Treatment, Living with HIV, Media

From CATIE, Sean R. Hosein reports on research that begins to paint a picture of what happens when people living with HIV are "lost to follow-up."

Investigating where patients go when they leave HIV care

- Previous research has found HIV-positive Canadians stop attending follow-up HIV appointments at rates between 11% and 24%. - Alberta researchers find that many patients “lost to follow-up” are seeking healthcare outside HIV services, often in hospital emergency rooms. - This research has implications for programs that seek to re-engage patients in HIV care. Potent combination anti-HIV therapy (ART) can reduce levels of HIV in the blood (viral load) to very low levels that cannot be de

U.S. simulation explores the intersection of PrEP and some sexually transmitted infections

published: October, 10, 2017 Written by // CATIE - HIV and Hep C Info Resource Categories // Social Media, As Prevention , Gay Men, CATIE, General Health, Treatment Guidelines -including when to start, Research, Health, Sexual Health, CATIE - HIV and Hep C Info Resource, Treatment, Lifestyle, Media

"The results of the researchers’ simulations show that PrEP should be considered as a package of interventions, of which STI screening and treatment are an important part. From Catie, Sean R. Hosein reports.

U.S. simulation explores the intersection of PrEP and some sexually transmitted infections

The use of medicines to prevent a person from becoming infected with HIV is called pre-exposure prophylaxis (PrEP). PrEP consists of two anti-HIV drugs—tenofovir DF and FTC—in one pill. In clinical trials with gay, bisexual and other men who have sex with men (MSM), PrEP has been highly effective in preventing the spread of HIV. According to a team of U.S. researchers who analysed data from several clinical trials, the consistent use of PrEP can reduce the risk of HIV infection “by more

Frailty, nerve injury and falls in middle-aged and older HIV-positive people

published: September, 15, 2017 Written by // CATIE - HIV and Hep C Info Resource Categories // Aging, Social Media, CATIE, General Health, Mental Health, Research, CATIE - HIV and Hep C Info Resource, International , Living with HIV, Media

From CATIE, Sean R. Hosein reports on a U.S. study that links such things as grip strength and gait speed with increased risk of falling.

Frailty, nerve injury and falls in middle-aged and older HIV-positive people

More HIV-positive people are living longer thanks to the use of potent combination anti-HIV therapy (ART). As HIV-positive people enter their middle age and senior years, they will have to grapple with one or more aging-related issues. One issue that can have a large impact on the health and quality of life of older people is falling. Older people who fall can injure themselves, and according to U.S. researchers, such injuries can make pre-existing problems, such as physical inactivity or weak

Ontario researchers find heart attacks occur earlier in people with HIV.

published: September, 12, 2017 Written by // CATIE - HIV and Hep C Info Resource Categories // Social Media, CATIE, Fitness and Exercise, Research, Health, Media

The researchers found that, on average, HIV-positive people tended to have a heart attack about 15 years before HIV-negative people. From CATIE, Sean R. Hosein reports on the CIHR HIV Trials Network Trial - Reprieve Study.

Ontario researchers find heart attacks occur earlier in people with HIV.

Studies have found that some HIV-positive people are at heightened risk for cardiovascular disease. The reasons for this are not clear but may be due to one or more of the following factors: smoking and/or other substance use elevated inflammation caused by HIV the presence of co-existing health conditions such as elevated blood pressure, type 2 diabetes, obesity exposure to older HIV medicines A number of studies from the U.S. have found that HIV-positive people who had a heart attac

Research finds that harm reduction and ART helped to reduce the spread of HIV in Vancouver

published: May, 02, 2017 Written by // CATIE - HIV and Hep C Info Resource Categories // Social Media, As Prevention , CATIE, Treatment Guidelines -including when to start, Research, CATIE - HIV and Hep C Info Resource, Health, Treatment

Sean R. Hosein of CATIE reports on research in Vancouver that attempted to study the relative impact that ART, harm reduction or both can have on the spread of HIV.

Research finds that harm reduction and ART helped to reduce the spread of HIV in Vancouver

In clinical trials, the early initiation of HIV treatment (ART) stabilizes the immune system and significantly reduces the risk of developing AIDS-related infections and cancers. This benefit of ART is so profound that researchers increasingly expect that many ART users will live into their senior years. Key to reaping the benefit of ART is achieving an undetectable level of HIV in the blood (viral load) and maintaining it through daily use of ART and regular checkups and laboratory monitori

The capsid inhibitor—a new class to enter clinical trials

published: April, 13, 2017 Written by // CATIE - HIV and Hep C Info Resource Categories // African, Caribbean and Black, Social Media, As Prevention , Gay Men, CATIE, Youth, General Health, Treatment Guidelines -including when to start, Women, CATIE - HIV and Hep C Info Resource, Sexual Health, Health, International , Treatment, Media

From CATIE: "This finding suggests that the capsid inhibitor has potential for intermittent dosing in people—perhaps every one or two months."

The capsid inhibitor—a new class to enter clinical trials

Most approved anti-HIV drugs work by interfering with an enzyme and/or protein that is needed by HIV-infected cells to make new viruses. A journey through the cell The capsid is the name given to the proteins that surround HIV’s genetic material. Upon HIV attaching itself to a target cell of the immune system, the virus sends its genetic material (RNA) into the cell. As the genetic material is surrounded by the capsid, it is protected from detection by the cell’s internal sensors. The ca

From the Conference on Retroviruses and Opportunistic Infections (CROI) 2017; new drugs, new hope and possible timelines

published: April, 07, 2017 Written by // CATIE - HIV and Hep C Info Resource Categories // Social Media, As Prevention , CATIE, Gay Men, Treatment Guidelines -including when to start, Research, CATIE - HIV and Hep C Info Resource, Treatment, Media

From CATIE, Sean R. Hosein reports on several new drugs that are in varying stages of development.

From the Conference on Retroviruses and Opportunistic Infections (CROI) 2017;  new drugs, new hope and possible timelines

Une version française est disponible ici. At the recent Conference on Retroviruses and Opportunistic Infections (CROI), which took place in Seattle from February 13 to 16, 2017, researchers presented data about new anti-HIV compounds in development, including the following: a new integrase inhibitor – bictegravir a new nuke (NRTI) – code-named GS-9131 a non-nuke (NNRTI) – doravirine a new protease inhibitor – code-named GS-PI1 a capsid inhibitor (a new cla

[12  >>